GLP-1 Receptor Agonist | Subcutaneous Injection | Once Weekly

Semaglutide is a GLP-1 receptor agonist — a medication that mimics the GLP-1 hormone to help regulate appetite and blood sugar. Originally developed for type 2 diabetes management, it was approved for chronic weight management in 2021 and has since become one of the most widely studied and prescribed weight loss medications in the world.

How it works: Semaglutide activates GLP-1 receptors in the brain and gut, reducing hunger signals and slowing the rate at which food leaves your stomach. This leads to decreased calorie intake without the intense hunger that derails most diets.

What the research shows:



In the landmark STEP 1 clinical trial, participants taking semaglutide 2.4 mg weekly lost an average of approximately 15% of their body weight over 68 weeks, compared to about 2.4% with placebo.



Over 90% of participants on the higher dose achieved at least 5% weight loss, and about one-third lost 25% or more of their starting weight.



Beyond weight loss, studies have shown semaglutide may reduce cardiovascular risk, improve liver health in patients with metabolic liver disease, and support better blood sugar control.